Technology readiness among UK-based cognitively unaffected older adults during the COVID-19 pandemic: potential implications for decentralised alzheimer's disease prevention trials

新冠疫情期间英国认知功能正常老年人的技术准备情况:对分散式阿尔茨海默病预防试验的潜在影响

阅读:1

Abstract

BACKGROUND: Alzheimer's disease (AD) remains a global health and socioeconomic burden. Telemedicine has been more widely used since the beginning of the COVID-19 pandemic and may be an effective strategy to mitigate the rising costs associated with AD. This study aimed to assess technology readiness among older adults at risk of developing dementia, with the goal of informing the design and delivery of technology-based approaches in AD prevention research. METHODS: Cognitively unaffected older adults (n = 226) from the CHARIOT PRO Substudy were invited to complete the CHARIOT Technology Questionnaire (CTQ). CTQ assessed technology experiences and attitudes, including 'technology readiness' via the Technology Readiness Index (TRI). RESULTS: Female participants scored, on average, lower TRI (M = 27.50, SD = 6.87) compared to males (M = 29.50, SD = 6.02). Furthermore, age predicted levels of technology readiness. Exploratory factor analysis determined two factors: "Technology Competence" (Factor 1) and "Technology Trepidation" (Factor 2). Gender differences were found for "Technology Competence" (but not "Technology Trepidation"), and age predicted "Technology Trepidation" (but not "Technology Competence"). DISCUSSION: Differences in gender, age, "Technology Competence", and "Technology Trepidation" may highlight those who need additional study and/or support in remote-based AD dementia prevention trials. CONCLUSIONS: COVID-19 has accelerated our adoption of 'digitalisation' in AD dementia research. A deeper understanding of the barriers to technology readiness may help inform future AD research studies. TRIAL REGISTRATION: The CHARIOT PRO SubStudy is registered with clinicaltrials.gov (NCT02114372).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。